- Home
- DSM vs ALDX Comparison
DSM vs ALDX Comparison
Compare DSM & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ALDX
- Stock Information
- Founded
- DSM 1989
- ALDX 2004
- Country
- DSM United States
- ALDX United States
- Employees
- DSM N/A
- ALDX N/A
- Industry
- DSM Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- ALDX Health Care
- Exchange
- DSM Nasdaq
- ALDX Nasdaq
- Market Cap
- DSM 304.0M
- ALDX 314.6M
- IPO Year
- DSM N/A
- ALDX 2014
- Fundamental
- Price
- DSM $6.02
- ALDX $5.14
- Analyst Decision
- DSM
- ALDX Strong Buy
- Analyst Count
- DSM 0
- ALDX 2
- Target Price
- DSM N/A
- ALDX $9.50
- AVG Volume (30 Days)
- DSM 161.7K
- ALDX 666.3K
- Earning Date
- DSM 01-01-0001
- ALDX 11-06-2025
- Dividend Yield
- DSM 3.97%
- ALDX N/A
- EPS Growth
- DSM N/A
- ALDX N/A
- EPS
- DSM N/A
- ALDX N/A
- Revenue
- DSM N/A
- ALDX N/A
- Revenue This Year
- DSM N/A
- ALDX N/A
- Revenue Next Year
- DSM N/A
- ALDX $63.48
- P/E Ratio
- DSM N/A
- ALDX N/A
- Revenue Growth
- DSM N/A
- ALDX N/A
- 52 Week Low
- DSM $4.69
- ALDX $1.14
- 52 Week High
- DSM $6.05
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- DSM 59.37
- ALDX 45.11
- Support Level
- DSM $5.93
- ALDX $4.70
- Resistance Level
- DSM $6.07
- ALDX $5.40
- Average True Range (ATR)
- DSM 0.05
- ALDX 0.29
- MACD
- DSM -0.00
- ALDX -0.03
- Stochastic Oscillator
- DSM 64.29
- ALDX 41.96
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.